Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa (HIDRA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04325607|
Recruitment Status : Recruiting
First Posted : March 27, 2020
Last Update Posted : March 27, 2020
The current surgical management for severe Hidradenitis suppurativa (HS) involves wide excision of affected skin, resulting in a large soft tissue defect. The soft tissue defect will then be managed with Negative Pressure Wound Therapy (NPWT) to promote healthy granulation tissue formation for wound coverage with Split skin graft (SSG). This long interval between excision and reconstruction could result in long in-patient stay, increased risk of hospital acquired infection and reduced patients' quality of life.
The investigators wish to evaluate the use of Negative Pressure Wound Therapy with instillation (NPWTi), which has potential to allow early wound coverage with SSG, as an alternative to the current standard of care. The investigators hypothesise that NPWTi reduces bacterial load on the wound and allows early wound coverage hence improves patient satisfaction and reduces cost and length of hospital stay.
|Condition or disease||Intervention/treatment||Phase|
|Hidradenitis Suppurativa||Procedure: Excision of HS followed by NPWTi Procedure: Excision of HS followed by NPWT||Not Applicable|
HS is a recurring chronic skin disease of the hair follicle that usually presents with painful and inflamed lesions in the sweat gland-bearing areas of the body. The lesions often progress to become chronic with pus discharge and scar formation resulting in significant disability.
Current surgical management for severe HS involves surgical removal of all involved hair bearing skin resulting in large areas of soft tissue loss which requires reconstruction. The wound is reconstructed by performing skin grafting, known as SSG, whereby a healthy layer of skin is transferred to the area of tissue loss. SSG enables rapid wound healing and has low risk of recurrence of HS. Skin grafting is often done a few weeks after excision of HS (delayed setting) to ensure higher success rate due to the infected nature of HS. During the interval between surgical removal of areas with HS and skin grafting, the wound is managed with a suction dressing known as the Negative Pressure Wound Therapy (NPWT) to promote formation of healthy wound bed. NPWT is a form of vacuum dressing which applies continuous suction pressure on the wound to remove fluids and bacteria from the wound bed.
The NPWT is highly successful in managing such wounds, however a novel and innovative improvement to this technology with an irrigation system, the Negative Pressure Wound Therapy with instillation (NPWTi), holds promise to enhance production of healthy wound bed and further reducing bacteria and infectious materials from the wound, enabling earlier wound coverage with SSG. The NPWTi involves irrigating and soaking the wound with fluid, followed by removal of the fluid via application of suction pressure at timed, regular intervals. The goal of the instillation therapy is to enable early application of SSG as wound irrigation has long been appreciated as beneficial for cleaning contaminated wounds.
The investigators wish to evaluate the NPWTi as an alternative to NPWT for current surgical management strategy of severe HS. The investigators wish to determine if NPWTi allows early wound coverage with SSG which improves patient satisfaction and reduces length of hospital stay. This research will further our knowledge about the human wound healing process and it may help improve treatment for future patients. The investigators plan to study up to 44 patients in total.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||44 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized Controlled Trial to Evaluate the Efficacy of Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa|
|Actual Study Start Date :||September 1, 2019|
|Estimated Primary Completion Date :||August 2022|
|Estimated Study Completion Date :||November 2022|
Experimental: Negative Pressure Wound Therapy with instillation
Patients in the treatment group will be initiated on VeraFlo instillation (NPWTi) therapy upon excision of HS
Procedure: Excision of HS followed by NPWTi
The NPWTi that will be used in this study will be the V.A.C. VERAFLO™ Therapy (KCI)
Other Name: VAC VERAFLO™ Therapy
Active Comparator: Negative Pressure Wound Therapy
Patient in the control group will be initiated on VAC therapy (NPWT) upon excision of HS
Procedure: Excision of HS followed by NPWT
The NPWT that will be used in this study will be the V.A.C.® Therapy(KCI)
Other Name: VAC Therapy
- The mean days to wound coverage with split skin graft (SSG) after excision of HS [ Time Frame: 2 weeks ]Mean days to wound coverage with split skin graft (SSG) after excision of HS in each treatment arm
- The difference in bacterial count on the wound after NPWTi against NPWT [ Time Frame: 2 weeks ]Reduction in the number of colony-forming unit (CFU) at each dressing change analysed using tissue culture of wound bed biopsies
- Proportion of wounds covered with SSG at 1 week post excision [ Time Frame: 1 week ]The proportion of wounds (in percentage) covered with split skin graft at 1 week post excision.
- Percentage of graft take at week 1 and week 4 [ Time Frame: 4 weeks ]Percentage of skin graft survival at week 1 and week 4
- Number of patients with recurrence of HS at 3 and 6 months [ Time Frame: 6 months ]Number of patients with recurrence of disease at 3 and 6 months
- Number of patients with improved Dermatology Life Quality Index (DLQI) [ Time Frame: 6 months ]Dermatology Life Quality Index (DLQI) will be used to measure the improvement in quality of life. Comparison will be made between DLQI during pre operative period and 6 months post operative
- The difference in cost between both treatments [ Time Frame: 6 months ]Data on the total cost of treatment between both treatment groups will be compared. The total cost will combine the cost of procedures, cost of devices, cost of inpatient stay and cost of clinic follow ups.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04325607
|Contact: Muholan Kanapathy, PhD||020 7794 firstname.lastname@example.org|
|Royal Free NHS Foundation Trust Hospital London||Recruiting|
|London, United Kingdom, NW3 2QG|
|Contact: Ibby Younis 020 7794 0500 ext 35556 email@example.com|
|Principal Investigator: Ibby Younis, Phd|
|Study Director:||Ash Mosahebi||Royal Free NHS Foundation Trust London|